GLP-1 Treatment Potential Indication in Obese patients: Review of Adverse Effects and Efficacy

Dr.Abdulrahman Saad Sulaiman, Nadeen Omar Saleh Helmi, Haya Abdul-Mohsen Saleh Al-Faleh, Alyaa Mohammed Rafie Banjar, Abdulaziz Aiyidh Sayir Aljiayyd, Abdulaziz Eidan Alghamdi, Samah Salih Almowalad, Jehad Ahmed Alluhaybi, Ahmed Saeed Alghamdi; Amwaj Faisal Tayyib Ageeli, Faisal Fahad Alsharif, Faisal Saleh Almohmmadi, Hisham Aiydh Alharbi, Hani Fahad Alharbi, Ahmed Ali Alsharif

doi:10.63278/jicrcr.vi.540

GLP-1 Treatment Potential Indication in Obese patients: Review of Adverse Effects and Efficacy

Authors

Dr.Abdulrahman Saad Sulaiman, Nadeen Omar Saleh Helmi, Haya Abdul-Mohsen Saleh Al-Faleh, Alyaa Mohammed Rafie Banjar, Abdulaziz Aiyidh Sayir Aljiayyd, Abdulaziz Eidan Alghamdi, Samah Salih Almowalad, Jehad Ahmed Alluhaybi, Ahmed Saeed Alghamdi
Amwaj Faisal Tayyib Ageeli, Faisal Fahad Alsharif, Faisal Saleh Almohmmadi, Hisham Aiydh Alharbi, Hani Fahad Alharbi, Ahmed Ali Alsharif

DOI:

https://doi.org/10.63278/jicrcr.vi.540

Keywords:

Glucagon-like peptide-1 receptor agonists, obesity.

Abstract

Obesity is a chronic, multifactorial disease linked to various comorbidities, including cardiovascular disease, diabetes, and certain cancers. Traditional management approaches such as lifestyle modifications often fail to produce sustainable results, necessitating pharmacological interventions. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially approved for glycemic control in type 2 diabetes, have emerged as effective agents for weight management. This review evaluates the efficacy of GLP-1 RAs, including semaglutide and liraglutide, in promoting weight loss and improving metabolic health in obese patients. The paper also examines the adverse effects associated with their use and discusses potential strategies for optimizing their role in obesity treatment.

Downloads

Published

2024-11-20

How to Cite

Dr.Abdulrahman Saad Sulaiman, Nadeen Omar Saleh Helmi, Haya Abdul-Mohsen Saleh Al-Faleh, Alyaa Mohammed Rafie Banjar, Abdulaziz Aiyidh Sayir Aljiayyd, Abdulaziz Eidan Alghamdi, Samah Salih Almowalad, Jehad Ahmed Alluhaybi, Ahmed Saeed Alghamdi, & Amwaj Faisal Tayyib Ageeli, Faisal Fahad Alsharif, Faisal Saleh Almohmmadi, Hisham Aiydh Alharbi, Hani Fahad Alharbi, Ahmed Ali Alsharif. (2024). GLP-1 Treatment Potential Indication in Obese patients: Review of Adverse Effects and Efficacy . Journal of International Crisis and Risk Communication Research , 792–798. https://doi.org/10.63278/jicrcr.vi.540